Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00467-021-05111-x http://scihub22266oqcxt.onion/10.1007/s00467-021-05111-x 34021797!8140325!34021797     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pediatr+Nephrol 2021 ; 36 (11): 3771-3776 Nephropedia Template TP {{tp|p=34021797|t=2021. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?|pdf=|usr=}}{{34021797}} gab.com Text Favipiravir use in children with COVID-19 and acute kidney injury: is it safe JO: Pediatr Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=34021797 #FOAvip BACKGROUND: The rising number of infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (popularly known as COVID-19) has brought to the fore new antiviral drugs as possible treatments, including favipiravir. However, there is currently no data regarding the safety of this drug in patients with kidney impairment. The aim of this paper, therefore, is to share our experience of the use of favipiravir in pediatric patients affected by COVID-19 with any degree of kidney impairment. METHODS: The study enrolled pediatric patients aged under 18 years and confirmed as suffering from COVID-19 and multisystem inflammatory syndrome in children (MIS-C) with any degree of kidney injury, who were treated with favipiravir at the time of admission. RESULTS: Out of a total of 11 patients, 7 were diagnosed with MIS-C and 4 with severe COVID-19. The median age of the cases was 15.45 (9-17.8) years and the male/female ratio was 7/4. At the time of admission, the median serum creatinine level was 1.1 mg/dl. Nine patients were treated with favipiravir for 5 days, and 2 patients for 5 days followed by remdesivir for 5-10 days despite kidney injury at the time of admission. Seven patients underwent plasma exchange for MIS-C while 2 severely affected cases underwent continuous kidney replacement therapy (CKRT) as well. One severe COVID-19 patient received plasma exchange as well as CKRT. Serum creatinine values returned to normal in mean 3.07 days. CONCLUSIONS: Favipiravir seems a suitable therapeutic option in patients affected by COVID-19 with kidney injury without a need for dose adjustment. Twit Text FOAVip Favipiravir use in children with COVID-19 and acute kidney injury: is it safe ????Pediatr Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=34021797 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34021797 #FOAvip English Wikipedia <ref>{{Cite pmid|34021797}}</ref> Favipiravir use in children with COVID-19 and acute kidney injury: is it safe? #MMPMID34021797 Ozsurekci Y; Oygar PD; Gurlevik SL; Kesici S; Ozen S; Kurt Sukur ED; Gulhan B; Topaloglu R; Bayrakci B; Cengiz AB Pediatr Nephrol 2021[Nov]; 36 (11): 3771-3776 PMID34021797show ga BACKGROUND: The rising number of infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (popularly known as COVID-19) has brought to the fore new antiviral drugs as possible treatments, including favipiravir. However, there is currently no data regarding the safety of this drug in patients with kidney impairment. The aim of this paper, therefore, is to share our experience of the use of favipiravir in pediatric patients affected by COVID-19 with any degree of kidney impairment. METHODS: The study enrolled pediatric patients aged under 18 years and confirmed as suffering from COVID-19 and multisystem inflammatory syndrome in children (MIS-C) with any degree of kidney injury, who were treated with favipiravir at the time of admission. RESULTS: Out of a total of 11 patients, 7 were diagnosed with MIS-C and 4 with severe COVID-19. The median age of the cases was 15.45 (9-17.8) years and the male/female ratio was 7/4. At the time of admission, the median serum creatinine level was 1.1 mg/dl. Nine patients were treated with favipiravir for 5 days, and 2 patients for 5 days followed by remdesivir for 5-10 days despite kidney injury at the time of admission. Seven patients underwent plasma exchange for MIS-C while 2 severely affected cases underwent continuous kidney replacement therapy (CKRT) as well. One severe COVID-19 patient received plasma exchange as well as CKRT. Serum creatinine values returned to normal in mean 3.07 days. CONCLUSIONS: Favipiravir seems a suitable therapeutic option in patients affected by COVID-19 with kidney injury without a need for dose adjustment. |*COVID-19 Drug Treatment[MESH] |*Renal Elimination[MESH] |Acute Kidney Injury/drug therapy/immunology/*physiopathology/virology[MESH] |Adenosine Monophosphate/administration & dosage/analogs & derivatives/pharmacokinetics[MESH] |Adolescent[MESH] |Alanine/administration & dosage/analogs & derivatives/pharmacokinetics[MESH] |Amides/*administration & dosage/pharmacokinetics[MESH] |COVID-19/*complications/immunology/virology[MESH] |Child[MESH] |Creatinine/blood[MESH] |Dose-Response Relationship, Drug[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Glomerular Filtration Rate[MESH] |Humans[MESH] |Male[MESH] |Pyrazines/*administration & dosage/pharmacokinetics[MESH] |SARS-CoV-2/isolation & purification[MESH] |Systemic Inflammatory Response Syndrome/complications/*drug therapy/immunology/virology[MESH]Favipiravir use in children with COVID-19 and acute kidney injury: is (epmc).pdf DeepDyve Pubget Overpricing